Pancreatic Cancer

Tumor Treating Fields were determined safe to use as a fronline therapy for unresectable pancreatic cancer.

In a phase 3 trial, five-year overall survival was nearly doubled when capecitabine was added to gemcitabine for patients with pancreatic cancer.

Algenpantucel-L failed to improve OS for patients with pancreatic cancer in a phase 3 trial.

Nurses and oncologists need to give portal vein thrombosis a closer look, according to one oncolgy nurse.

In the analysis, there was as much as a 92 percent difference in median overall survival (OS) seen between patients treated in randomized controlled trials and "real world" data.

Scientists are investigating a host of new treatment types that may change the outlook for those with pancreatic cancer.

Thanks to the NPF, patients with pancreatic diseases can now find healthcare organizations that prove excellent in treating their conditions.

Exciting new treatment options for patients with pancreatic cancer are on the rise, thanks to organizations such as the Lustgarten Foundation.

This study of Onivyde, 5-FU and leucovorin for the treatment of patients with metastatic pancreatic cancer was presented at the 2016 Gastrointestinal Cancers Symposium.

The approval was based on data from the phase 3 NAPOLI-1 trial, which demonstrated a 1.9-month improvement in overall survival (OS) with the addition of Onivyde to 5-FU and leucovorin.